Articles publicats

Articles publicats 3 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
13 p, 1.3 MB Toxicity of Asciminib in Real Clinical Practice : Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors / Pérez-Lamas, Lucía (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Luna, Alejandro (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Boque, Concepcion (Hospital Duran i Reynals-ICO) ; Xicoy, Blanca (Universitat Autònoma de Barcelona. Departament de Medicina) ; Giraldo, Pilar (Hospital Quirón Salud Zaragoza) ; Pérez López, Raúl (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Ruiz Nuño, Concepción (Hospital Regional Universitario de Málaga) ; De las Heras, Natalia (Hospital Universitario de León) ; Mora Casterá, Elvira (Hospital Universitari i Politècnic La Fe (València)) ; López Marín, Javier (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Segura Díaz, Adrián (Hospital Universitario de Gran Canaria Dr. Negrín) ; Gómez, Valle (Hospital Universitario de la Princesa (Madrid)) ; Vélez Tenza, Patricia (Hospital del Mar (Barcelona, Catalunya)) ; Sierra Pacho, Magdalena (Hospital Clínico Universitario (Salamanca)) ; Vera Goñi, Juan Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Moreno Vega, Melania (Hospital Doctor José Molina Orosa de Lanzarote) ; Álvarez Larrán, Alberto (Hospital Clínic i Provincial de Barcelona) ; Cortés, Montse (Hospital General de Granollers) ; Pérez-Encinas, Manuel (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Carrascosa Mastell, Patricia (Consorci Hospitalari Provincial de Castelló) ; Angona, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ; Rosell, Ana (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Lakhwani, Sunil (Hospital Universitario de Canarias (La Laguna)) ; Colorado Araujo, Mercedes (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Ramila, Elena (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Cervero, Carlos (Hospital Virgen de La Luz (Cuenca)) ; Cuevas, Beatriz (Hospital Universitario de Burgos) ; Villalón Blanco, Lucía (Hospital Universitario Fundación Alcorcón) ; De Paz, Raquel (Hospital Universitario La Paz (Madrid)) ; Paz Coll, Antonio (Hospital Universitario Puerto Real (Cadis)) ; Fernández, María José (Hospital Universitari Doctor Peset (València)) ; Felipe Casado, Luis (Hospital Virgen de la Salud (Toledo)) ; Alonso-Domínguez, Juan Manuel (Hospital Universitario Fundación Jiménez Díaz) ; Anguita Arance, María Magdalena (Complejo Hospitalario de Jaén) ; Salamanca Cuenca, Araceli (Hospital Universitario de Jerez (Jerez de la Frontera)) ; Jiménez-Velasco, Antonio (Hospital Regional Universitario de Málaga) ; Prendes, Santiago Osorio (Hospital General Universitario Gregorio Marañón) ; Santaliestra, Marta (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Lis Chulvi, María José (Hospital General Universitario de Valencia) ; Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ; Garcia-Gutierrez, Valentin (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid))
After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world setting have been reported, but a detailed analysis of the toxicity profile and the influence of prior intolerance to classical tyrosine kinase inhibitors (TKIs) has not been performed. [...]
2023 - 10.3390/cancers15041045
Cancers, Vol. 15 (february 2023)  
2.
24 p, 760.0 KB Immunotherapies against HER2-Positive Breast Cancer / Duro-Sánchez, Santiago (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Román Alonso, Macarena (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
A wide range of treatments are available for HER2-positive breast cancer, which have greatly improved the prognosis and quality of life of these patients. However, resistance to HER2-targeted or untargeted therapies is common in clinical practice and is associated with metastasis, recurrence, and cancer-related death. [...]
2023 - 10.3390/cancers15041069
Cancers, Vol. 15 (february 2023)  
3.
19 p, 2.3 MB B Cells in Breast Cancer Pathology / Li, Mengyuan (King's College London) ; Quintana, Angela (Vall d'Hebron Institut d'Oncologia) ; Alberts, Elena (The Francis Crick Institute) ; Hung, Miu Shing (King's College London) ; Boulat, Victoire (King's College London) ; Martí, Mercè (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Grigoriadis, Anita (School of Cancer and Pharmaceutical Sciences) ; Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí"
B cells in the tumour microenvironment and lymph nodes have affirmed their role in breast cancer pathology. Multiplex imaging, single cell, and spatial transcriptomics of cancer patients' breast carcinomas and lymph nodes have illustrated the diversity and spatial context of B cells in this disease. [...]
2023 - 10.3390/cancers15051517
Cancers, Vol. 15, Issue 5 (February 2023) , art. 1517  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.